A Global Biopharmaceutical Enterprise
Leading the allogeneic stem cell movement, Stemedica stands out as
a highly respected and established biotechnology company that prides
itself on values of transparency, collaboration and technology
leadership. Currently, Stemedica maintains a facility compliant with the
Food and Drug Administration. This facility also remains in good
standing with cGMP (Current Good Manufacturing Practices) as licensed by
California’s Department of Health and Human Services. Stemedica’s
product lines for research and clinical trial studies include retinal
pigment epithelial cells, mesenchymal stem cells derived from adult bone
marrow and neural stem cells.
Critical to Stemedica’s success is its commitment to quality processes, government compliance and a dedicated, knowledgeable team. Through a unique process using low oxygen manufacturing, Stemedica is able to produce large quantities of top-of-the-line products from single source donations. The process begins with donor screening for human pathogens and then moves onto specimen processing and the development of a primary culture. This culture is placed in Stemedica’s master cell bank, after which time the tissue culture expands. Stem cells are then placed into the working cell bank to be ready for final testing and, eventually, clinical trials.